Mankind Pharma Limited (NSE: MANKIND, BSE: 543904) – Board Approval of Strategic Investment & Majority Stake Acquisition in Armed Cell Therapeutics

Date of Announcement: 15 October 2026

---

Introduction

Mankind Pharma Limited (listed on NSE as MANKIND and BSE as 543904) disclosed the outcomes of its Board of Directors meeting held on 15 Oct 2026. The Board approved a substantial additional investment in its Dutch subsidiary and the acquisition of a controlling interest in a European biotechnology firm developing next‑generation CAR‑T cancer therapies.

---

Board Approval Summary

Item	Decision
Additional investment	Up to EUR 45 million in Mankind Pharma (Netherlands) B.V., raising the total authorized investment to EUR 50 million (including the previously approved EUR 5 million).
Acquisition	Purchase of 70 % of Armed Cell Therapeutics B.V. (ACTx) through Mankind Netherlands, funded with EUR 48 million in cash, to be paid in instalments.
Meeting timings	Commenced at 06:00 pm IST and concluded at 07:00 pm IST.

---

Investment Details

• Target vehicle: Mankind Pharma (Netherlands) B.V. (wholly‑owned subsidiary, incorporated 13 Aug 2026; authorized share capital EUR 50 mn, paid‑up EUR 0.02 mn, turnover nil).
• Purpose of additional capital: To finance the EUR 48 mn cash consideration for the 70 % stake in ACTx and support the Company’s long‑term, innovation‑led pharmaceutical strategy.
• Related‑party nature: The investment into Mankind Netherlands is a related‑party transaction (wholly‑owned subsidiary) but is exempt under Regulation 23(5) of the SEBI Listing Regulations. The subsequent investment in ACTx is not a related‑party transaction.

---

Acquisition of Armed Cell Therapeutics (ACTx)

Aspect	Details
Target entity	Armed Cell Therapeutics B.V., Belgium‑incorporated biotechnology company.
Industry	Pharmaceutical / Biotechnology (CAR‑T cell therapy).
Stake acquired	70 % (majority control).
Consideration	Cash – EUR 48 million, payable in instalments as per the definitive agreement.
Strategic fit	Provides Mankind Pharma entry into next‑generation armed CAR‑T therapies targeting non‑Hodgkin lymphoma and small‑cell lung cancer, aligning with its goal to build a global, innovation‑driven pipeline.
Regulatory approvals	Subject to any approvals required under the laws of the host country (Belgium/Netherlands).
Completion timeline	To be determined as per the definitive agreement; no specific date disclosed.

ACTx Highlights (as per press release):

• Lead programs in non‑Hodgkin lymphoma and small‑cell lung cancer.
• R&D teams located in the US and EU.
• Founded by industry veterans including Paul Stoffels (Chair), John Mellors (CSO), and Peter Verhaeghe.

---

Regulatory & Compliance Notes

• The disclosures satisfy Regulation 30 of the SEBI Listing Regulations and the SEBI Master Circular No. HO/49/14/14(7)2025‑CFD‑POD2/I/3762/2026.
• The transaction between the Company and its wholly‑owned subsidiary (Mankind Netherlands) is exempt from related‑party transaction provisions under Regulation 23(5).
• No change in the Company’s shareholding percentage in Mankind Netherlands – it remains a wholly‑owned subsidiary.

---

Strategic Rationale

• Diversification into high‑growth biotech: The acquisition marks Mankind Pharma’s first major foray into CAR‑T cell therapy, a fast‑growing segment of oncology therapeutics.
• Global innovation platform: Leveraging ACTx’s pipeline and experienced leadership to develop differentiated, next‑generation cancer treatments.
• Long‑term value creation: Aligns with the Company’s vision of becoming a research‑focused, globally competitive pharmaceutical player while maintaining its core domestic market strengths.

---

Forward‑Looking Statements & Risk Factors

The press release contains forward‑looking statements regarding the anticipated benefits of the ACTx acquisition and the Company’s growth strategy. Key risk factors highlighted include:

• Cash‑flow projections and funding requirements.
• Industry and market conditions, including competition in oncology therapeutics.
• Ability to manage rapid growth and integration of a biotech asset.
• Obtaining necessary regulatory approvals in multiple jurisdictions.
• Currency exchange fluctuations (EUR/INR).
• Potential delays in R&D timelines or clinical outcomes.

Investors are advised to review the full Safe Harbour Statement included in the announcement for a comprehensive list of risks.

---

Contact Information

Function	Contact Person	Email	Phone
Investor Relations	Prakash Agarwal	investor.relations@mankindpharma.com	+91‑11‑46846700
Corporate Communication	Natasha Raj	natasha.raj@mankindpharma.com	011‑46846700 Ext: 3201
PR Agency (Adfactors)	Smit Shah / Apoorva Sharma	smit.shah@adfactorspr.com / apoorva.sharma@adfactorspr.com	+91 9870789596 / +91 9999739452

---

This article presents a factual synthesis of the Board‑approved investment and acquisition disclosed by Mankind Pharma Limited on 15 Oct 2026. No external information has been added.